Time: 17:00-18:30 CET

Speaker: Ursula Theuretzbacher, CEFAIA (Austria)

Moderator: Prabhavathi Fernandes, formerly Cempra Pharmaceuticals (USA)

In this webinar, Ursula Theuretzbacher will discuss the following aspects of non-traditional antibacterial therapeutics:

  • Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline
  • These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation.
  • Some of these approaches require novel preclinical efficacy models to predict clinical outcome
  • Pathogen-specific or even patient-specific strategies dominate this field
  • A major challenge will be to show efficacy in clinical trials

For the Q&A session, Ursula will be joined by Laura Piddock (GARDP).

Register now for this live webinar including interactive Q&A session on 4 February 2020, 17:00-18:30 CET (find your time zone here).

If you have questions or comments, please let us know. Do so by submitting them via the ‘Talk to an expert’ feature or contact us by email: revive@gardp.org.